Heat Biologics Inc. is doing everything it can to keep going with its Phase II bladder cancer immunotherapy, announcing several cost-reduction measures April 7, but it will be tough going in a crowded field that will soon see the long shadow of Roche's PD-L1 inhibitor atezolizumab.
The Durham, N.C., biotech announced a 22% staff cut as well as compensation reductions for its remaining leadership team and the voluntary resignations of two board members